ESTRO 2025 - Abstract Book

S2294

Interdisciplinary – Health economics & health services research

ESTRO 2025

cost was €300.00 [IQR, 172.50–600.00], with only 2 patients having travel expenses covered. The median duration of stay in the city was 37.5 days [IQR, 17.5–50.0]. Accommodations included rented houses for 57.1%, staying with family or friends for 20%, and hotels or bed & breakfast arrangements for 20%. The median cost for accommodation was €2300.00 [IQR, 1250.00–3050.00]. Commuting costs to the therapy facility totaled €77.50 [IQR, 18.75–205.00], and meal expenses amounted to €350.00 [IQR, 200.00–585.00]. Thirty-one patients (39.7%) reported work disruption, with a median absence of 30 days [IQR, 15.0–40.0]; however, only 21 (67.7%) received compensation during this period. When accompanied by a caregiver, the median absence from work for the caregiver was 15.0 days [IQR, 7.0–22.5]. Financial considerations posed challenges for many patients, as reflected in responses to the Likert scale assessment (Fig. 1). Notably, a significant portion of patients expressed concern that the financial burden could limit access to PT for others facing similar health issues.

Fig.1: Distribution of Responses to Financial and Relocation-Related Stress Factors Conclusion:

Proton therapy imposes substantial financial and logistical burdens on patients and their families, particularly for those requiring relocation. These challenges highlight the need for targeted support mechanisms, including financial aid, patient housing options, and workplace accommodations. Understanding these barriers is crucial for improving access to PT and mitigating its associated stressors.

Keywords: financial toxicity, logistics, proton therapy